RxDoctor Payments Data

Janice Maldonado, MD

Neurology · Tampa, FLNPI 1639199748

Payments from drug & device makers

$517,248in general payments, 2019–2025

Across 301 payments — averaging $1718.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • H. Lundbeck A S$202K
  • Eli Lilly$153K
  • Genentech, Inc.$106K
  • Roche Products Limited$45K
  • AstraZeneca$10K
  • AbbVie$455
  • plus $756 from 12 others
$1,850in research payments, 2019–2025

Across 1 payment — averaging $1850.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$2K

What the payments were for

  • Food & beverage$1,234100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
H. Lundbeck A S112$201,912
Eli Lilly25$152,978
Genentech, Inc.41$105,905
Roche Products Limited73$45,043
AstraZeneca1$10,200
AbbVie(2 entities)21$455
Amgen4$175
Pfizer8$157
Sanofi3$125
Teva Pharmaceuticals USA, Inc.2$52
Lundbeck LLC2$49
EMD Serono, Inc.2$45
Biohaven Pharmaceutical Holding Company Ltd.2$34
SK Life Science, Inc.1$32
Biogen1$30
Tonix Medicines, Inc.1$25
Janssen Scientific Affairs, LLC1$18
Impel Pharmaceuticals LLC1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$517,248 in reported general payments places this provider in the 90th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida

Medicare billing

Part B allowed, 2024
$77,707
Medicare patients
126
Services billed
9,038

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Kesimpta PenOfatumumab59$541,525
CopaxoneGlatiramer Acetate80$530,474
UbrelvyUbrogepant140$174,844
QuliptaAtogepant94$118,515
Nurtec OdtRimegepant Sulfate76$114,821
TecfideraDimethyl Fumarate12$110,508
Emgality PenGalcanezumab-Gnlm106$87,296
Aimovig AutoinjectorErenumab-Aooe67$65,171
BotoxOnabotulinumtoxina33$41,378
Dalfampridine ErDalfampridine126$30,691
GlatopaGlatiramer Acetate11$21,887
Glatiramer Acetate14$19,863
Topiramate ErTopiramate16$15,048
Emgality SyringeGalcanezumab-Gnlm18$14,366
Dimethyl Fumarate36$11,208

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Copaxone$52$530,47480 claims
AbbVieUbrelvy, Qulipta, Botox$455$334,738267 claims
PfizerNurtec Odt$157$114,82176 claims
BiogenTecfidera$30$110,50812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,434 neurology providers in Florida.

Other neurology in Tampa

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →